Sharechat Logo

Daily ShareChat: Fisher & Paykel Healthcare

By Jenny Ruth

Tuesday 7th December 2010

Text too small?
 Jenny Ruth

The star of Fisher & Paykel Healthcare's first-half result was respiratory humidity which sale sales rise 15% in constant currency terms, says Sarndra Urlich, an analyst at First NZ Capital.

"The RH performance was particularly impressive when you consider that Fisher & Paykel had to contend with some macro headwinds. . . and the fact that there had been some stockpiling of flow generators at the previous comparable period," Urlich says.

"OSA (obstructive sleep apnea), in contrast, reported anaemic, albeit explainable, growth at close to 1%," she says.

Market leader ResMed achieved 10% to 12% growth while the market in general grew 17% to 18% but Fisher & Paykel's poor OSA performance should be made up for in the next two half years with the full rollout of its new ICON product.

"The key positive catalyst for Fisher & Paykel, in our view, will be when and if the ICON gets serious traction in the US," Urlich says.

"The fact that Fisher & Paykel is getting positive feedback regarding this platform is reassuring. Unfortunately, the market will have to wait until the second half of 2011/the first-half of 2012 for transparency around this."

Another meaningful catalyst would be if the New Zealand dollar declined.

Rating: Underperform.


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZ dollar rally may limit profit gains for Fisher and Paykel Healthcare, brokerage says
Shares in Fisher and Paykel Healthcare third-best performer on NZX 50 after raising earnings forecast
Fisher and Paykel Healthcare raises 2014 earnings forecast on higher sales, margins
F and P Healthcare shares jump to highest in more than 2 years on profit outlook
F and P Healthcare beats 2013 guidance, forecasts boost in 2014 profit; shares gain to 2 1/2 year high
F and P Healthcare shares rise to two-year high as First NZ raises rating on better outlook
Fisher & Paykel Healthcare
F and P Healthcare lifts guidance as sales grow, margins widen; shares rally
F&P Healthcare 1H profit rises 18%, on record sales, wider margins